Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation

In conclusion, the present study identified canagliflozin as a potent inhibitor of human EC proliferation. The anti-proliferative action of canagliflozin is observed in ECs isolated from both the venous and arterial circulation, and is partly due to the blockade of cyclin A expression. In addition, this study found that canagliflozin inhibits tube formation in cultured ECs and mouse aortic rings. Notably, these actions are specific for canagliflozin and not seen with other SGLT2 inhibitors. The ability of canagliflozin to exert these pleiotropic effects on EC function may contribute to both the adverse and salutary actions of this drug on cardiovascular function in T2DM patients. Ethics Statement This study was approved by the institutional Animal Care-Use Committees of the University of Missouri and the Truman VA Hospital (Columbia, MO, USA) and performed in accordance with the National Research Council’s Guide 152 for the Care and Use of Laboratory Animal. Author Contributions GB, SMB, SBB, KP, LM-L, and WD participated in research design. GB, SMB, ZD, and KP conducted experiments and performed data analysis. GB, SMB, SBB, LM-L, KP, and WD wrote or contributed to writing of the manuscript. Funding This work was supported by the American Diabetes Association [#1-17-IBS-290 to WD], the Department of Veterans Affairs BLR&D [IK2 BX002030 to SBB], and the National Institutes of Health [HL136386 to SBB and HL088105 to LM-L]. This work was also supported by t...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research

Related Links:

Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part BAuthor(s): Yanhua Liu, Yang Li, Shanshan Dong, Lu Han, Ruixin Guo, Yourong Fu, Shenghu Zhang, Jianqiu Chen
Source: Journal of Hazardous Materials - Category: Environmental Health Source Type: research
Authors: Musio F Abstract INTRODUCTION: Anemia has and will continue to be a central theme in medicine particularly as clinicians are treating a burgeoning population of complex multi-organ system processes. As a result of multiple randomized controlled trials (RCTs), meta-analyses, and societal recommendations overly restrictive paradigms and under-administration of erythropoiesis stimulating agents (ESAs) have likely been followed by clinicians among all specialties. AREAS COVERED: A review of anemia in the context of chronic kidney disease, hematologic malignancies and cancer is presented with focus on the e...
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research
Authors: Zhang W, Xu JZ, Lu XH, Li H, Wang D, Wang JG Abstract PURPOSE: We hypothesise that dietary sodium intake interacts with serum uric acid to influence blood pressure (BP) in children and adolescents. In the present study, we investigated ambulatory BP in relation to hyperuricaemia, dietary sodium intake and their interaction in children and adolescents with hypertension. MATERIALS AND METHODS:  A total of 616 study participants were 10-24 years old and had primary hypertension diagnosed after admission in a specialised inpatient ward. Ambulatory BP monitoring was performed during hospitalisat...
Source: Blood Pressure - Category: Hematology Tags: Blood Press Source Type: research
Authors: Sabet Sarvestani F, Azarpira N Abstract Heart and cerebral infarctions, as two important ischemic diseases, lead to the death of tissues due to inadequate blood supply and high mortality worldwide. These statuses are started via blockage of vessels and depletion of oxygen and nutrients which affected these areas. After reperfusion and restoration of oxygen supply, more severe injury was mediated by multifaceted cascades of inflammation and oxidative stress. microRNAs (miRNAs) as the regulator of biological and pathological pathways can adjust these conditions by interaction with their targets. Also, miRNAs...
Source: Immunological Investigations - Category: Allergy & Immunology Tags: Immunol Invest Source Type: research
Publication date: January 2021Source: Urology Case Reports, Volume 34Author(s): Nina Al-Saadi, Safa Al-Musawi, Yousuf Khan, Daben Dawam
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
Publication date: Available online 10 October 2020Source: Journal of Vascular Surgery: Venous and Lymphatic DisordersAuthor(s): N.G. Shah, B.C. Wible, J.A. Paulisi, M. Zaki, P. Lamparello, A. Sista, M. Sadek, G.R. Jacobowitz, T.S. Maldonado
Source: Journal of Vascular Surgery: Venous and Lymphatic Disorders - Category: Surgery Source Type: research
Publication date: Available online 9 October 2020Source: Cirugía Española (English Edition)Author(s): Victoria Lucas-Guerrero, Mireia Pascua-Solé, José Luis Ramos Rodríguez, Anna Trinidad Borrás, Carlos González de Pedro, José María Jover Navalón, Pere Rebasa, Eduardo M. Targarona Soler, Xavier Serra-Aracil, on behalf of the Comisión Nacional de la Especialidad de Cirugía General y del Aparato Digestivo, de la Sección de Formación de la Asociación Española de Cirujanos
Source: Cirugia Espanola - Category: Surgery Source Type: research
Source: European Journal of Sport Science - Category: Sports Medicine Authors: Source Type: research
Authors: Matti B, Zargar-Shoshtari K Abstract Prostate cancer represents a significant health burden worldwide. The cancer incidence had substantially increased since the introduction of prostate specific antigen (PSA) in cancer screening. This had led to considerable debates among health professionals and epidemiologists, since PSA as a screening tool seemed to be far from perfect. In New Zealand, the controversy was quite prominent in the last three decades, with some advocating the benefits of screening, while others concerned regarding the risk of harms. With the absence of an organised screening programme and ...
Source: New Zealand Medical Journal - Category: General Medicine Tags: N Z Med J Source Type: research
CONCLUSION: The proposed PHARMAC criteria will give access to these important drugs to those people with T2DM who will likely benefit the most. PMID: 33032305 [PubMed - in process]
Source: New Zealand Medical Journal - Category: General Medicine Tags: N Z Med J Source Type: research
More News: Academia | Acetic Acid | Adenocarcinoma | Adenoviruses | Anesthesia | Anesthesiology | Angioplasty | Biotechnology | Brain | Brain Cancers | Canagliflozin | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Chemistry | Chile Health | Chloride | Chronic Kidney Disease | Clinical Trials | Coronary Angioplasty | Dapagliflozin | Databases & Libraries | Diabetes | Diabetes Mellitus | Diabetes Type 1 | Diabetes Type 2 | Drugs & Pharmacology | Empagliflozin | Endocrinology | Epidemiology | Epithelial Cancer | Eye Cancers | Forxiga | Gastroschisis Repair | Genetics | Heart | Heart Attack | Hemorrhagic Stroke | Insulin | Invokana | Januvia | Japan Health | Jardiance | Laboratory Medicine | Liver | Medical Ethics | Milk | Mitochondrial Disease | Netherlands Health | Neurology | Nutrition | Penicillin | Peripheral Vascular Disease (PVD) | Physiology | Primary Care | Prostate Cancer | Radish | Reproduction Medicine | Retinoblastoma | SGLT2 Inhibitors | Sodium | Spain Health | Statistics | Stroke | Students | Study | Switzerland Health | Thrombosis | Universities & Medical Training | Urology & Nephrology | USA Health